Juvenile Systemic Sclerosis, a Retrospective Epidemiological Study on a French Cohort

Uvenile Systemic Sclerosis, a Retrospective Epidemiological Study on a French Cohort

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06019234

Acronym

JSSc

Enrollment

Registered

2023-08-31

Start date

2023-03-03

Completion date

2024-10-03

Last updated

2023-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Systemic Sclerosis

Keywords

Systemic Sclerosis, Juvenile Systemic Sclerosis, Immunosuppressive treatments

Brief summary

Scleroderma is an inflammatory attack of the vessels leading to localized or multisystemic sclerosis. It is a rare autoimmune pathology in pediatrics. The incidence in pediatrics is very low (about 4 per million according to an American) and therefore the data on the pathology very poor, especially on the therapeutic level. The proposed immunosuppressive treatments are extrapolated from data in adults. The evolution of connectivity does not seem quite identical to the evolution of adult scleroderma, adaptation of treatments seems judicious. However, data on the evolution under therapy in children are still poor. Complications related to the pathology, iatrogeny and diagnostic delay are the first causes of mortality from this pathology and deserve to be studied and if possible avoided. The main hypothesis of the research being to bring together the experiences of the various reference and competence centers in France concerning the clinical presentation, management and follow-up of children with systemic sclerosis.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 17 Years

Healthy volunteers

Inclusion criteria

* Minor subject (\<18 years old) * Diagnosis of systemic sclerosis between 01/01/2012 and 30/06/2022. * Subject (and/or his parental authority) who has not expressed, after being informed, his opposition to the reuse of his data for the purposes of this research.

Exclusion criteria

\- Subject (or his parents) having expressed his (their) opposition to participating in the study

Design outcomes

Primary

Measure	Time frame
The therapeutic response was evaluated by the EULAR DAS 28 -CRP	at 6 months

Countries

France

Contacts

Primary ContactAriane ZALOSZYC, MD

ariane.zaloszyc@chru-strasbourg.fr33 3 88 12 77 42

Backup ContactRouba BECHARA, MD

Rouba.bechara@chru-strasbourg.fr33 3 88 12 77 42

Outcome results